FMS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Fresenius Medical Care AG is not a strong buy for a beginner, long-term investor at this time. The technical indicators are bearish, options sentiment is neutral to slightly positive, and analysts have consistently lowered price targets with mixed ratings. While the company's financial performance in Q4 2025 was strong, the lack of positive trading signals and the presence of headwinds in 2026 suggest waiting for a better entry point.
The MACD is negative and expanding downward, RSI is neutral at 37.163, and moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock price is near its pivot level of 23.492, with support at 22.602 and resistance at 24.382. Overall, the technical indicators suggest a bearish trend.
Strong Q4 2025 financial performance with revenue up 8.82% YoY, net income up 433.64% YoY, and EPS up 454.17% YoY. Gross margin also improved by 9.65%.
Analysts have consistently lowered price targets, citing headwinds such as slow treatment volume growth, potential Affordable Care Act subsidy expirations, and incremental training costs. Technical indicators are bearish, and no significant insider or hedge fund activity has been observed.
In Q4 2025, Fresenius Medical Care AG reported strong financial growth: revenue increased by 8.82% YoY to $5.9 billion, net income surged by 433.64% YoY to $380.7 million, EPS rose by 454.17% YoY to 1.33, and gross margin improved by 9.65% to 27.39%.
Analysts have a mixed to negative outlook. Deutsche Bank and Morgan Stanley have lowered price targets and maintained Hold or Underweight ratings. Goldman Sachs downgraded the stock to Neutral, citing several headwinds for 2026, including slow treatment volume growth and potential regulatory challenges.
